Table 3.
Review of literature. LC: local control; NSCLC: non-small cell lung cancer.
| Authors/year | Indications | Dose concept (dose specification) | LC (NSCLC) | LC (metastases) |
|---|---|---|---|---|
| Blomgren et al. 1995 [3] | Metastases NSCLC | 3 × 10 − 2 × 15 Gy, 65% isodose | 3/3 100% | 13/14 93% |
| Uematsu et al. 1998 [33] | Metastases NSCLC | 5–15 fx, 30–76 Gy, 80% isodose | 22/23 96% | 42/43 98% |
| Uematsu et al. 2001 [34] | NSCLC | 5–10 fx, 50–60 Gy, 100% isodose, 80% coverage | 47/50 96% | – 2_ |
| Nagata et al. 2002 [23] | Metastases NSCLC | 4 × 10–12 Gy, 100% isodose | 31/33 94% | 31/33 94% |
| Onimaru et al. 2003 [25] | Metastases NSCLC | 8 fx, 40–60 Gy, 80–100% isodose | 20/25 80% | 18/20 90% |
| Lee et al. 2003 [20] | Metastases NSCLC | 3–4 × 10 Gy, 90% isodose | 8/9 89% | 23/25 92% |
| Timmerman et al. 2003 [31] | NSCLC | 3 × 8 – 3 × 20 Gy, 80% isodose | 31/37 84%, no relapse ≥ 18 Gy | |
| This study | NSCLC | 5 × 7–8 Gy, 90% isodose | 3/3 100% | 31/36 86% |